Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Deloitte
Daiichi Sankyo
Accenture
Covington
Colorcon
Cipla
Mallinckrodt

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

« Back to Dashboard

Clinical Trials for Cardene In 4.8% Dextrose In Plastic Container

Trial ID Title Status Sponsor Phase Summary
NCT00325793 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Withdrawn Facet Biotech Phase 2 To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
NCT00765648 Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed EKR Therapeutics, Inc Phase 4 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cardene In 4.8% Dextrose In Plastic Container

Condition Name

Condition Name for Cardene In 4.8% Dextrose In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Vasospasm 1
Nontraumatic Intracerebral Hemorrhage, Multiple Localized 1
Hypertensive Urgency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cardene In 4.8% Dextrose In Plastic Container
Intervention Trials
Hypertension 2
Cerebral Hemorrhage 2
Vasospasm, Intracranial 1
Emergencies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cardene In 4.8% Dextrose In Plastic Container

Trials by Country

Trials by Country for Cardene In 4.8% Dextrose In Plastic Container
Location Trials
United States 14
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cardene In 4.8% Dextrose In Plastic Container
Location Trials
Texas 2
Illinois 2
Pennsylvania 1
North Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cardene In 4.8% Dextrose In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cardene In 4.8% Dextrose In Plastic Container
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cardene In 4.8% Dextrose In Plastic Container
Clinical Trial Phase Trials
Withdrawn 2
Recruiting 2
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cardene In 4.8% Dextrose In Plastic Container

Sponsor Name

Sponsor Name for Cardene In 4.8% Dextrose In Plastic Container
Sponsor Trials
Mayo Clinic 1
University of Michigan 1
EKR Therapeutics, Inc 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cardene In 4.8% Dextrose In Plastic Container
Sponsor Trials
Other 17
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Healthtrust
Farmers Insurance
Merck
Chubb
Cantor Fitzgerald
Dow
Cerilliant
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.